Related Experiment Video

Updated: Jun 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Therapies for diabetic dyslipidaemia

D S H Bell1, F Al Badarin, J H O'Keefe

  • 1Department of Endocrinology, University of Alabama, Birmingham, AL 35205, USA. dshbell@yahoo.com

Diabetes, Obesity & Metabolism
|January 6, 2011
PubMed

Insights

Managing diabetic dyslipidaemia is crucial for reducing cardiac risk in diabetes patients. Effective management involves controlling blood glucose and lipid levels, often requiring combination therapies and lifestyle changes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Diabetic dyslipidaemia presents a significant cardiovascular risk in diabetic patients.
  • It is characterized by high triglycerides, low high-density lipoprotein (HDL), and small, dense low-density lipoprotein (LDL) particles.
  • Correcting non-HDL cholesterol is a primary therapeutic objective.

Purpose of the Study:

  • To outline the importance of managing diabetic dyslipidaemia for cardiovascular risk reduction.
  • To discuss therapeutic strategies for improving lipid profiles in diabetic patients.
  • To highlight the role of glycaemic control and specific medications like pioglitazone.

Main Methods:

  • Review of current therapeutic recommendations for diabetic dyslipidaemia.
  • Emphasis on lifestyle modifications and pharmacological interventions.
  • Discussion of combination therapies including statins, nicotinic acid, omega-3 fats, and bile acid sequestrants.

Main Results:

  • Pioglitazone shows efficacy in improving diabetic dyslipidaemia, inflammation, and hyperglycaemia.
  • Statins are recommended for most type 2 diabetes patients to lower LDL cholesterol to <100 mg/dl.
  • Combination therapies are often necessary to achieve optimal lipid levels, targeting triglycerides and HDL-C.

Conclusions:

  • Comprehensive management of diabetic dyslipidaemia is essential for mitigating cardiac events.
  • Achieving target lipid levels typically requires a multi-faceted approach combining lifestyle changes and pharmacotherapy.
  • Further research may be needed to clarify the role of fibrates in reducing adverse cardiovascular events in this population.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...